Breast Cancer: The Importance of Local Control

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

Award-winning work by Dr. Marie Overgaard, of the Department of Oncology, Aarhus University Hospital, Denmark, gives new hope of longer survival for women with breast cancer. Dr. Overgaard’s work shows that treating the primary

Award-winning work by Dr. Marie Overgaard, of the Department of Oncology, Aarhus University Hospital, Denmark, gives new hope of longer survival for women with breast cancer. Dr. Overgaard’s work shows that treating the primary tumor with an optimal combination of surgery, radiotherapy and adjuvant chemotherapy markedly reduces the risk of local recurrences. Dr. Overgaard therefore calls for the reversal of current trends towards less aggressive local treatment for primary breast cancers.

Over the past 25 years, major improvements in survival from breast cancer have been achieved by giving adjuvant therapy,” said Dr. Overgaard at the 1997 European Cancer Conference. “But, paradoxically, there has been a tendency to treat the primary tumor less aggressively than before, on the basis that breast cancer is a systemic disease and that local treatment to the primary tumor will not affect survival.”

The Danish Breast Cancer Trials show that this view is mistaken. In these trials, 3,000 premenopausal and postmenopausal women received postmastectomy radiation and adjuvant systemic therapy, or systemic adjuvant therapy alone. Strikingly, during the 10-year follow-up period, the women who received systemic adjuvant therapy alone were four times more likely to develop local recurrences than the women who received combined therapy. 

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content